Global R&D, Production, and Sales System Supports Overseas Expansion

Huang Wei, President of Henlius, stated that the first shipment of H drug to India not only demonstrates the efficient operation of the company's global supply system but also serves as another example of China's original innovative drugs going global.

Since its establishment in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities spanning the entire industry chain, from R&D and production to commercial operations. Its commercial production facilities have obtained GMP certifications from China, the EU, and the U.S., enabling production and quality control in compliance with international standards and ensuring global supply.

In terms of R&D pipeline, Henlius has developed approximately 50 molecules covering oncology, autoimmune diseases, ophthalmic diseases, and other areas, while advancing tumor immunotherapy combinations based on H drug. To date, the company has secured approvals for six products in China and four internationally, with five marketing applications under review by the NMPA, U.S. FDA, and EMA. It has also initiated over 30 clinical trials globally for 19 products and licensed its products to partners in major markets like Europe and the U.S. as well as emerging markets.

The entry of H drug into the Indian market is a concrete step in Henlius' globalization strategy. With the continuous improvement of its global R&D, production, and sales system and deeper collaboration with partners worldwide, more innovative drugs are expected to benefit patients globally.

Financially, Henlius reported revenue of RMB 5.724 billion in 2024, a year-on-year increase of 6.1%, with global sales of H drug growing 17.2%. Industry analysts predict that as H drug expands further in international markets, overseas revenue will likely account for a larger share, becoming a core driver of future growth. (Li Ping)